Stay updated with breaking news from Additional Ehave Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MIAMI, Jan. 11, 2021 -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced it has licensed revolutionary AI to unlock
[December 28, 2020] Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value MIAMI, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the âCompanyâ), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Company's Board of directors has elected to sell 100% of its Mycotopia Therapies subsidiary to 20/20 Global Inc. (OTC Pink: TWGL) for $350,000 while simultaneously acquiring approximately 75.77% of 20/20 Globalâs outstanding...
Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets MIAMI, Dec. 16, 2020 — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced KetaDASH www.ketadash.com, an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine. Ehave, Inc. has entered into an asset purchase agreement to acquire the tangible and intangible assets ...